US pharma major Eli Lilly has released new data demonstrating more patients with moderately to severely active Crohn's ...

Lilly announces positive results from phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease: Indianapolis Tuesday, October 15, 2024, 18:00 Hrs [IST] Eli Lilly a ...

Johnson & Johnson reported third-quarter earnings with adjusted EPS of $2.42, surpassing expectations. Sales rose 5.2% to $22.47B. J&J updated its 2024 adjusted EPS guidance, lowering it slightly to ...

Shares of drug maker Eli Lilly ($LLY) were little changed at the time of writing despite announcing results from its Phase 3 ...

On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of ...

Data show more patients treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab New data are first-of-its-kind analysis of microscopic mucosal resolution that go beyon ...

(RTTNews) - Eli Lilly and Company (LLY) Monday announced 1-year histologic data from the Phase 3 VIVID-1 study of mirikizumab in people with Crohn's disease, a type of inflammatory bowel disease.

Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's ...